A rapidly internalizing, tetravalent antibody-drug conjugate leads to high selectivity in T-ALL cell lines due to surface antigen depletion
Year: 2026
Type: article
Abstract: A key concern with the use of antibody-drug conjugates (ADCs) is the presence of tumor-associated antigens (TAAs) on non-diseased tissue. While ADCs leverage the upregulation of TAAs on diseased cells to create the therapeutic window, basal expression on healthy cells underlies on-target, off-tumor side effects. Engineering ADCs to further increase specificity is thus a major consideration in next-generation drug development. A promising strategy is the use of multivalent antibodies with low monovalent affinity to specifically target high-expressing cells that can be avidly bound. This, however, does not rule out multivalent binding on cells with low expression but high-density antigen patches, ultimately limiting selectivity. Addressing this, we introduce an alternative selectivity mechanism based on surface antigen depletion. Specifically, we generated a tetravalent, rapidly internalizing ADC specific to the T-cell acute lymphoblastic leukemia (T-ALL) target CD7. We show that this format can bind CD7high and CD7low cells with similar strength due to the avidity effect, while also inducing total antigen depletion due to fast internalization kinetics. Thus, total ADC uptake is limited by available surface antigen levels, resulting in extreme selectivity toward CD7high cells. CD7low cells are conversely spared, due to complete depletion of surface antigen before a lethal ADC dose can be internalized. Ultimately, this provides a method to potentially reduce on-target, off-tumor side effects, consequently improving ADC specificity even when low-expressing cells are susceptible to avid binding.
Source: mAbs
Authors: Mustafa Abdellatif(Conceptualization, Data curation, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing), Marlene Rauschmayer(Investigation, Resources, Writing – review & editing), Semjon Willier(Formal analysis, Investigation, Resources, Writing – review & editing), Jonathan Schwach(Resources, Writing – review & editing), Sandra M. Kydd(Investigation, Resources, Validation, Writing – review & editing), Dhruv Mehra(Resources, Writing – review & editing), Daniel Nixdorf(Formal analysis, Resources, Validation, Writing – review & editing), Luis Fonseca-Ornelas(Investigation, Methodology, Visualization, Writing – review & editing), Sophie Brameyer(Formal analysis, Investigation, Writing – review & editing), Jyotirmoy Rajurkar(Validation, Writing – review & editing), Heinrich Flaswinkel(Resources, Writing – review & editing), Elisabeth Kremmer(Resources, Writing – review & editing), Ralf Strasser(Supervision, Writing – review & editing), Marion Subklewe(Supervision, Writing – review & editing), Carolin Daniel(Supervision, Writing – review & editing), Tobias Feuchtinger(Supervision, Writing – review & editing), Heinrich Leonhardt(Conceptualization, Funding acquisition, Resources, Supervision, Writing – review & editing), Andreas Stengl(Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing)
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,575
Awards: European Partnership for Personalised Medicine, G1485794032, TRR 338: LETSIMMUN Lymphozyten Engineering für Therapeutische Synthetische Immunität, G2591531669, G3212532952, Integrated multi-angle research and training network to eradicate leukemia minimal residual disease, TRR 355: Heterogenität und funktionelle Spezialisierung regulatorischer TZellen in unterschiedlichen Mikromilieus, G9000380415
OpenAlex ID: W7235262629
